natgillin/translations-raw huggingface dataset:
Fotodinamično zdravljenje (PDT, photodynamic therapy) s PhotoBarrom je indicirano v primeru odprave displazije visoke stopnje (HGD, high-grade dysplasia) pri bolnikih z Barrettovim požiralnikom (BP).
Photodynamic therapy (PDT) with PhotoBarr is indicated for ablation of high-grade dysplasia (HGD) in patients with Barrett's Oesophagus (BO).
Fotodinamično zdravljenje s PhotoBarrom je 2-stopenjski proces.
Photodynamic therapy with PhotoBarr is a 2-stage process.
Fotodinamično zdravljenje s PhotoBarrom mora opraviti zdravnik, ki ima izkušnje z endoskopskimi laserskimi postopki oz. se lahko opravi le pod nadzorom takega zdravnika.
Photodynamic therapy with PhotoBarr should be performed only by, or under the supervision of, a physician with experience in endoscopic laser procedures.
Fotodinamično zdravljenje s PhotoBarrom naj uporabijo le zdravniki, ki so usposobljeni za endoskopsko uporabo PDT in le v tistih ustanovah, ki so primerno opremljene za ta postopek.
Photodynamic therapy with PhotoBarr should be applied by physicians trained in endoscopic use of PDT and only in those facilities properly equipped for the procedure.
Fotodinamično zdravljenje s PhotoBarrom smo preučevali izključno pri bolnikih, ki ne trpijo zaradi hudih bolezenskih stanj, kot so kongestivna srčna odpoved v napredovali fazi ali hude pljučne bolezni, ki bi lahko vplivale na primernost bolnikov za kirurške posege.
Photodynamic therapy with PhotoBarr has exclusively been studied in patients not suffering from severe medical conditions, such as congestive heart failure of advanced stage or serious pulmonary conditions that might impair the eligibility of patients for surgical procedures.
Fotodinamično zdravljenje s porfimer-natrijem je 2-stopenjski proces.
Photodynamic therapy with PhotoBarr is a 2-stage process.
FP+H N = 294
FP +H N = 294
FP+H: Флуоропиримидин/цисплатин + Herceptin FP: Флуоропиримидин/цисплатин a Съотношение на вероятностните съотношения (Odds ratio)
FP + H: Fluoropyrimidine/cisplatin + Herceptin FP: Fluoropyrimidine/cisplatin a Odds ratio
FPV (PLI IV).....................................................................................................................  103.5 CCID50
FPV (PLI IV)....................................................................................................................  103.5 CCID50.
FPV (PLI IV).....................................................................................................................  103.5 CCID50 FeLV рекомбинантен вирус canarypox (vCP97)............................................................  107.2 CCID50
FPV (PLI IV).....................................................................................................................  103.5 CCID50 FeLV recombinant canarypox virus (vCP97)...................................................................  107.2 CCID50.
FPV/RTV 700 mg/100 mg BID (n = 105)
FPV/RTV 700 mg/100 mg
FPV/RTV 700 mg/100 mg BID (n = 105)
FPV/RTV 700 mg/100 mg BID (n= 105)
FPV/RTV 700 mg/100 mg BID (n = 434)
FPV/RTV 700 mg/100 mg BID (n= 434)
FPV/RTV BID спрямо LPV/RTV BID
FPV/RTV BID vs LPV/RTV BID
FPV/RTV BID – Фозампренавир с ритонавир два пъти дневно, LPV/RTV BID – Лопинавир/ритонавир два пъти дневно
FPV/RTV BID – Fosamprenavir with ritonavir twice daily, LPV/RTV BID – Lopinavir / ritonavir twice daily
FPV/RTV)
inhibitors may cause
FPV/RTV)
Use with caution.
Fra 24 timer til 48 timer efter behandlingsstart
24 hours to 48 hours after treatment initiation
Fra 24 timer til 48 timer efter behandlingsstart
At treatment initiation
Fra 24 timer til 48 timer efter en dosisændring
24 hours to 48 hours after dose change
Fra 24 timer til 48 timer efter en dosisændring
from 24 hours to 48 hours after treatment initiation from 24 hours to 48 hours after dose change
Fra utlandet Tlf: +46 8 616 95 85
Fra utlandet Tlf.: +46 8 616 95 85
Framingham, MA 01701-9322 САЩ
Framingham, MA 01701-9322 USA
France
Eesti
France
France Portugal
France
France România
France
France.
France
Hrvatska
France
Italia
France
Latvija
France
Lietuva
France
Nederland
France
Polska
France
Portugal
France
Österreich
France
Ελλάδα
France Portugal
Österreich
France România
France
France sanofi-aventis france Tél : 0 800 222 555
France sanofi-aventis France Tél: 0 800 222 555
FRANCE.
FRANCE
Frekvencia
Frequency
Frekvencia menej časté.
Frequency uncommon.
Frekvencie nižšie uvedených nežiaducich reakcií sa klasifikujú ako veľmi časté (≥ 1/10), časté (≥ 1/100 až < 1/10) a menej časté (≥ 1/1 000 až < 1/100).
The frequencies of the adverse reactions reported below are classified as very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100).
Frekvens
(mL/min)
Frekvens
Frequency
Frekvens Infusionstid Behandlingstid
Dose of ceftazidime/avibactam
Frekvensen av biverkningar anges enligt följande konvention:
The frequency of adverse reactions is defined using the following convention:
Frekvensen av biverkningar anges enligt följande:
The frequency of adverse reactions is defined using the following convention:
Frekvensen av detta är okänd (se avsnitt 4.4).
The frequency of this is unknown (see section 4.4).
Frekvenserna definieras som mycket vanliga (≥ 1/10), vanliga (≥ 1/100, < 1/10) eller mindre vanliga (≥ 1/1 000, < 1/100).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) or uncommon (≥ 1/1,000 to < 1/100).
Frekvenskategorin mindre vanliga bedömdes utgående från en statistisk beräkning baserad på det totala antalet patienter som exponerats för emtricitabin i dessa kliniska studier (n = 1 563).
The frequency category of uncommon was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in these clinical studies (n = 1,563).
Frekvent och upprepad användning av svampmedel från samma klass kan öka risken för att utveckla resistens mot denna klass av svampmedel.
Frequent and repeated use of antifungals from the same class may increase the risk of development of resistance to that class of antifungals.
FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
FREMSTILLERE AF DE BIOLOGISK AKTIVE STOFFER OG FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE
MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
FREMSTILLERENS BATCHNUMMER
MANUFACTURER'S BATCH NUMBER
FREMSTILLERENS BATCHNUMMER
MANUFACTURER’S BATCH NUMBER
Fresenius Kabi Nederland BV Tel: +31 (0)30 698 52 70
KBM Pharma OÜ Tel: +372 733 8080
Frimley Business Park
Frimley Business Park Frimley
Frimley Business Park Frimley
Frimley Business Park Frimley, Camberley
Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, Обединено кралство
Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, United Kingdom
Frimley Camberley
Camberley
Frimley, Camberley, Surrey GU16 7SR Обединено кралство
Frimley, Camberley, Surrey GU16 7SR United Kingdom.
Fråga apotekspersonalen hur man kastar läkemedel som inte längre används.
Ask your pharmacist how to dispose of medicines no longer required.
Fråga apotekspersonalen hur man kastar läkemedel som inte längre används.
Do not throw away any medicines via wastewater or household waste.
Fråga veterinären hur man gör med mediciner som inte längre används.
Ask your veterinary surgeon how to dispose of medicines no longer required.
FSH е гонадотропин – вид хормон, който играе важна роля за фертилитета и възпроизводството при хора.
FSH is a gonadotropin, a type of hormone that plays an important role in human fertility and reproduction.
FSH е гонадотропин, вид хормон, който играе важна роля при фертилитета и репродукцията при хората.
FSH is a gonadotropin, a type of hormone that plays an important role in human fertility and reproduction.
FSH стимулира образуването на зрели яйцеклетки в яйчниците.
FSH stimulates the production of eggs in the ovaries.
FSH стимулира образуването на яйцеклетки
FSH stimulates the production of eggs
FSH, който се прилага в комбинация с Luveris, също стимулира овулацията.
FSH, which is used together with Luveris, also stimulates ovulation.
FTC = емтрицитабин; TAF = тенофовир алафенамид; TFV = тенофовир, N/A = не е приложимо Данните са представени като средни стойности (%CV). a n = 24 юноши (GS-US-292-0106); n = 19 възрастни (GS-US-292-0102) б n = 23 юноши (GS-US-292-0106, популация ФК анализ) в n = 539 (TAF) или 841 (TFV) възрастни (GS-US-292-0111 и GS-US-292-0104, популация ФК анализ)
FTC = emtricitabine; TAF = tenofovir alafenamide; TFV = tenofovir, N/A = not applicable Data are presented as mean (%CV). a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102) b n = 23 adolescents (GS-US-292-0106, population PK analysis) c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis)
FTC/TDF плюс потенциран атазанавир
FTC/TDF plus boosted atazanavir
Fungitraxx 10 mg/ml oral lösning för burfåglar
Fungitraxx 10 mg/ml oral solution for ornamental birds
Fungitraxx 10 mg/ml oral lösning för burfåglar Itrakonazol
Fungitraxx 10 mg/ml oral solution for ornamental birds Itraconazole
Fungitraxx 10 mg/ml oral lösning itrakonazol
Fungitraxx 10 mg/ml oral solution itraconazole
Fusarium spp.: 11 от 24 пациенти с доказана или вероятна фузариоза са лекувани успешно с позаконазол 800 mg дневно в разделени дози за средно 124 дни и не повече от 212 дни.
Fusarium spp.: 11 of 24 patients who had proven or probable fusariosis were successfully treated with posaconazole 800 mg/day in divided doses for a median of 124 days and up to 212 days.
Fusarium spp.: Седем (3 с пълен, 4 с частичен отговор) от 17 пациенти са лекувани успешно с вориконазол.
Fusarium spp.: Seven (3 complete, 4 partial responses) of 17 patients were successfully treated with voriconazole.
Fusarium spp.: Седем (3 с пълен, 4 с частичен отговор) от 17 пациенти са лекувани успешно с вориконазол.
Fusarium spp.: Seven (3 complete,4 partial responses) of 17 patients were successfully treated with voriconazole.
FUSION е рандомизирано, двойносляпо проучване, което оценява 12 или 16 седмици на лечение със софосбувир и рибавирин при пациенти, които не са постигнали ТВО с предходна интерферон-базирана терапия (пациенти с рецидиви и пациенти без отговор).
FUSION was a randomised, double-blinded study that evaluated 12 or 16 weeks of treatment with sofosbuvir and ribavirin in subjects who did not achieve SVR with prior interferon-based treatment (relapsers and nonresponders).
Fusion-инхибитори
Fusion Inhibitors
Fusobacterium-arter.
Fusobacterium spp.
Fuzeon + ООЛ 90 mg 2 пъти дневно (N=661)
Fuzeon + OB 90 mg bid (N=661)
Fuzeon 90 mg/ml прах за инжекционен разтвор
Fuzeon 90 mg/ml powder for solution for injection Enfuvirtide
Fuzeon 90 mg/ml прах и разтворител за инжекционен разтвор
Fuzeon 90 mg/ml powder and solvent for solution for injection
Fuzeon 90 mg/ml прах и разтворител за инжекционен разтвор Енфувиртид
Fuzeon 90 mg/ml powder and solvent for solution for injection Enfuvirtide
Fuzeon е показан в комбинация с други антиретровирусни лекарствени продукти за лечение на пациенти, заразени с НІV-1, които са лекувани неуспешно с терапевтични схеми, съдържащи поне един лекарствен продукт от всеки от следните антиретровирусни класове: протеазни инхибитори, ненуклеозидни инхибитори на обратната транскриптаза и нуклеозидни инхибитори на обратната транскриптаза, или които имат непоносимост към предишни антиретровирусни терапевтични схеми (вж. точка 5.1).
Fuzeon is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non- nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens (see section 5.1).
Fuzeon не лекува HIV инфекцията.
Fuzeon is not a cure for HIV infection.
Fuzeon се използва за лечение на човешкия имунодефицитен вирус (НІV) – в комбинация с други антиретровирусни лекарства при пациенти, инфектирани с НІV.
Fuzeon is used for the treatment of Human Immune deficiency Virus (HIV) - in combination with other antiretroviral medicines in patients infected with HIV.
Fuzeon се прилага като инжекция от 1 ml точно под кожата – наречено „подкожна” инжекция.
Fuzeon is given as a 1 ml injection just below the skin – called a ‘subcutaneous’ injection.
Fuzeon съдържа активното вещество енфувиртид и принадлежи към група лекарства, наречени
Fuzeon contains the active substance enfuvirtide and belongs to a group of medicines called ‘antiretrovirals’.
Fuzeon съдържа натрий
Fuzeon contains sodium
Fuzeon съдържа по-малко от 1 mmol натрий (23 mg) на доза, т.е. практически не съдържа натрий.
Fuzeon contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially ‘sodium-free’.
Fuzeon трябва да се прилага като инжекция под кожата – наречено „подкожна” инжекция.
Fuzeon must be given as an injection just below the skin – called a ‘subcutaneous’ injection.
FVC обем като абсолютна стойност (l)
FVC absolute volume (L)
FVIII:C на Iblias може да се измери в плазмата с едноетапни тестове за кръвосъсирване, както и чрез хромогенен тест при използване на рутинните за всяка лаборатория методи.
The FVIII:C of Iblias can be measured in plasma with a one-stage coagulation assay as well as with a chromogenic assay using the routine methods of the laboratory.
FVIII:C на Kovaltry може да се измери в плазмата с едноетапни тестове за кръвосъсирване, както и чрез хромогенен тест при използване на рутинните за всяка лаборатория методи.
The FVIII:C of Kovaltry can be measured in plasma with a one-stage coagulation assay as well as with a chromogenic assay using the routine methods of the laboratory.
FXIII е проензим (про- трансглутаминаза), който се активира от тромбина в присъствието на Ca2+.
FXIII is a pro-enzyme (pro-transglutaminase), which is activated by thrombin in the presence of Ca2+.
Fycompa 0,5 mg/ml
Fycompa 0.5 mg/ml
Fycompa 0,5 mg/ml перорална суспензия
Fycompa 0.5 mg/ml oral suspension
Fycompa 0,5 mg/ml перорална суспензия е бяла до почти бяла суспензия.
Fycompa 0.5 mg/ml oral suspension is a white to off-white suspension.
Fycompa 0,5 mg/ml перорална суспензия перампанел
Fycompa 0.5 mg/ml oral suspension perampanel
Fycompa 10 mg филмирани таблетки
Ferric oxide, black (E172) Fycompa 10 mg film-coated tablets
Fycompa 10 mg филмирани таблетки 10 mg – опаковки по 7, 28, 84 и 98
Fycompa 10 mg film-coated tablets 10 mg – packs of 7, 28, 84 and 98
Fycompa 10 mg филмирани таблетки Перампанел
Fycompa 10 mg film-coated tablets Perampanel
Fycompa 12 mg филмирани таблетки 12 mg – опаковки по 7, 28, 84 и 98
Fycompa 12 mg film-coated tablets 12 mg – packs of 7, 28, 84 and 98
Fycompa 12 mg филмирани таблетки Перампанел
Fycompa 12 mg film-coated tablets Perampanel
Fycompa 2 mg филмирани таблетки Перампанел
Fycompa 2 mg film-coated tablets Perampanel
Fycompa 2 mg, 4 mg, 6 mg, 8 mg, 10 mg и 12 mg филмирани таблетки
Fycompa 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg film-coated tablets
Fycompa 4 mg филмирани таблетки 4 mg – опаковки по 7, 28, 84 и 98
Fycompa 4 mg film-coated tablets 4 mg – packs of 7, 28, 84 and 98
Fycompa 4 mg филмирани таблетки Перампанел
Fycompa 4 mg film-coated tablets Perampanel
Fycompa 6 mg филмирани таблетки 6 mg – опаковки по 7, 28, 84 и 98
Fycompa 6 mg film-coated tablets 6 mg – packs of 7, 28, 84 and 98
Fycompa 6 mg филмирани таблетки Перампанел
Fycompa 6 mg film-coated tablets Perampanel
Fycompa 8 mg филмирани таблетки 8 mg – опаковки по 7, 28, 84 и 98
Fycompa 8 mg film-coated tablets 8 mg – packs of 7, 28, 84 and 98
Fycompa 8 mg филмирани таблетки Перампанел
Fycompa 8 mg film-coated tablets Perampanel
Fycompa е сравнен с плацебо като допълнение към текущо лечение за епилепсия.
Fycompa was compared with placebo as an addition to patients’ existing epilepsy treatment.
Fycompa може да Ви накара да се чувствате замаяни или сънливи, особено в началото на лечението.
Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment.
Fycompa може да Ви направи агресивни, гневни или буйстващи.
Fycompa may make you aggressive, angry or violent.
Fycompa може да повиши риска от падане, особено ако сте по-възрастни, което може да е в резултат на Вашето заболяване.
Fycompa may make you more likely to fall over, particularly if you are an older person; this might be due to your illness.
Fycompa може да понижи ефективността на определени хормонални контрацептиви като левоноргестрел.
Fycompa may make certain hormonal contraceptives such as levonorgestrel less effective.
Fycompa може да предизвика замаяност или сънливост, особено в началото на лечението.
Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment.
Fycompa не се препоръчва по време на бременност.
Fycompa is not recommended in pregnancy.
Fycompa се продава в опаковки по: Таблетки от 2 mg – опаковка по 7, 28 и 98
Fycompa is available in packs of: 2 mg tablet – pack of 7, 28 and 98
Fycompa трябва да се използва само като допълващо лечение към други антиепилептични лекарства.
Fycompa must only be used as an ‘add-on’ therapy to other anti-epileptic medicines.
FÖRTECKNING ÖVER HJÄLPÄMNEN
LIST OF EXCIPIENTS
FÖRTECKNING ÖVER HÖGSTA TILLÅTNA RESTMÄNGDER
STATEMENT OF THE MRLs
FÖRTECKNING ÖVER HÖGSTA TILLÅTNA RESTMÄNGDER (MRL)
STATEMENT OF THE MRLs
Färgen på Zinforo infusionslösningar varierar från klar via ljust gul till mörkt gul, beroende på koncentration och förvaringsförhållanden.
The colour of Zinforo infusion solutions ranges from clear, light to dark yellow depending on the concentration and storage conditions.
Fòti ùt 56, Budapest H-1047 Унгария
Fòti ùt 56, Budapest H-1047, Hungary
Fòti ùt 56., Budapest, 1047, Унгария
Fòti ùt 56., Budapest, 1047, Hungary
Följande biverkningar har rapporterats för enbart ceftazidim och/eller identifierats under fas 2 och fas 3 kliniska studier med Zavicefta.
The following adverse reactions have been reported with ceftazidime alone and/or identified during the Phase 2 and Phase 3 trials with Zavicefta.
Följande biverkningar kan förekomma med detta läkemedel:
The following side effects may happen with this medicine:
Följande biverkningar kan inträffa med detta läkemedel:
The following side effects may happen with this medicine:
Följande innehållsämnen i Inflacam finns i tabell 1 i bilagan till Kommissionens förordning (EU) nr 37/2010:
The active substance in Inflacam is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) 37/2010:
Följande uppgifter är endast avsedda för hälso- och sjukvårdspersonal: Viktigt: Läs produktresumén innan du förskriver.
The following information is intended for healthcare professionals only: Important: Please refer to the Summary of Product Characteristics before prescribing.
För aktiv immunisering av hund mot:
For active immunisation of dogs against:
För användning vid akut luftvägsinfektion tillsammans med lämplig antibiotikabehandling för att reducera kliniska symtom hos nötkreatur.
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
För användning vid diarré i kombination med oral rehydreringsbehandling för att reducera kliniska symtom hos kalvar, över 1 vecka gamla, och yngre icke lakterande nötkreatur.
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
För användning vid diarré i kombination med vätskebehandling via munnen för att reducera kliniska symtom hos kalvar, över 1 vecka gamla, och yngre icke lakterande nötkreatur.
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
För användning vid icke-infektiösa störningar i rörelseapparaten för att reducera symptom av hälta och inflammation.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
För användning vid störningar i rörelseapparaten som inte beror på infektion, för att reducera symptom av hälta och inflammation.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
För att behandla kräkning, i kombination med annan stödjande behandling.
For the treatment of vomiting, in combination with other supportive measures.
För att behandla och förebygga illamående som orsakas av kemoterapi.
For the treatment and prevention of nausea induced by chemotherapy.
För att förebygga illamående och kräkningar före, under och efter operation och förbättra återhämtning från generell anestesi efter användning av µ-opioidreceptoragonisten morfin.
For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
För att förebygga illamående som orsakas av kemoterapi Behandling och förebyggande behandling av kräkning (utom åksjuka)
Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness)
För att förebygga illamående som orsakas av kemoterapi och för behandling och förebyggande behandling av kräkning (utom åksjuka), (endast till hundar som är 8 veckor eller äldre)
For the prevention of nausea induced by chemotherapy and treatment and prevention of vomiting (except motion sickness), (only for dogs 8 weeks of age or older).
För att förebygga illamående som orsakas av kemoterapi och för behandling och förebyggande behandling av kräkning (utom åksjuka), endast till hundar som är 8 veckor eller äldre
For prevention of nausea induced by chemotherapy and treatment and prevention of vomiting (except motion sickness), only for dogs 8 weeks of age or older
För att förebygga illamående som orsakas av kemoterapi.
For the prevention of nausea induced by chemotherapy.
För att förebygga kräkning som orsakas av åksjuka.
For the prevention of vomiting induced by motion sickness.
För att förebygga kräkning, bör Cerenia injektionsvätska, lösning administreras mer än 1 timme i förväg.
To prevent vomiting, Cerenia solution for injection should be administered more than 1 hour in advance.
För att förebygga kräkning, förutom då detta orsakas av åksjuka.
For the prevention of vomiting except that induced by motion sickness.
För att förebygga och behandla kräkning i anslutning till behandling med Cerenia injektionsvätska, lösning och i kombination med annan stödjande behandling.
For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures.
För att förebygga perioperativt illamående och kräkningar och förbättra återhämtning från generell anestesi efter användning av µ-opioidreceptoragonisten morfin.
For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
För att minimera risken för intolerans, ska produkten blandas i müslifoder.
In order to minimise risk of intolerance, the product should be mixed into muesli feed.
För att minska risken för biverkningar bör den rekommenderade dosen inte överskridas.
To minimize the risk of adverse reactions, the recommended dose should not be exceeded.
För att stimulera aktiv immunitet hos hundar mot L. interrogans serogrupp Canicola serovar Canicola,
To stimulate active immunity in dogs against L. interrogans serogroup Canicola serovar Canicola,
För att säkerställa korrekt dosering, bör kroppsvikten bestämmas så exakt som möjligt för att undvika underdosering eller överdosering
To ensure correct dosage, body weight should be determined as accurately as possible to avoid underdosing or overdosing.
För att säkerställa rätt dos och för att undvika under- och överdosering ska fågelns/fåglarnas kroppsvikt fastställas så noggrant som möjligt.
To ensure the correct dose, and to avoid underdosing and overdosing, the bodyweight(s) of the bird(s) to be treated should be determined as accurately as possible.
För att uppnå bästa möjliga postoperativa smärtlindring, bör Inflacam ges 30 minuter före ett kirurgiskt ingrepp.
To obtain the best possible pain relieving post-surgery Inflacam should be administered 30 minutes before surgical intervention.